Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of etirinotecan pegol [NKTR 102] in patients with refractory solid tumours

Next Previous
X
Search
Trial Profile

Phase I study of etirinotecan pegol [NKTR 102] in patients with refractory solid tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etirinotecan pegol (Primary)
  • Indications Gastrointestinal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Nektar Therapeutics

    • Most Recent Events

    • 24 Oct 2008 Positive interim results were presented at the 20th EORTC -NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics', according to a Nektar media release.
    • 24 Oct 2008 In a media release, Nektar announced that the company expects to present complete results at additional scientific forums later this year.
    • 02 Jun 2008 Results have been presented at ASCO 2008; complete results are expected later in 2008, according to a Nektar Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top